Eli Lilly and Company Stock News

Eli Lilly (LLY -0.32%) is encouraged by trial data for its latest weight-loss and diabetes medications.

Novo Nordisk is banking on fresh leadership to help it reclaim the crown in the booming weight loss drug market. The Danish drugmaker last week abruptly announced that longtime CEO Lars Fruergaard Jorgensen is stepping down, as its obesity injection Wegovy loses ground to Eli Lilly's rival treatment, Zepbound.

Der einstige Highflyer Novo Nordisk zieht nach den jüngsten Enttäuschungen die Reißleine und tauscht den Chef aus. Wird nun alles besser?

Eli Lilly (LLY 3.47%) has a strong pipeline of new medicines that could increase the stock price.

Eli Lilly (LLY 3.47%) is gaining market share in a lucrative market that could be a catalyst for a stock price increase.

The company delivered 45% revenue growth in Q1 2025, driven by ZEPBOUND and MOUNJARO's strong performance in the obesity and diabetes markets. ZEPBOUND outperformed Novo Nordisk's WEGOVY in terms of weight loss, solidifying Lilly's leadership in the booming global anti-obesity drug market space. The company's oral GLP-1 agonist orforglipron showed promising phase 3 results, positioning the comp...

The global weight-loss drug market, once dominated by Novo Nordisk, is undergoing a dramatic transformation. On Friday, the Danish pharmaceutical giant announced it would replace its long-serving chief executive, Lars Fruergaard Jorgensen, as the company faces mounting pressure from rivals and a sharp slide in its stock value.

Eli Lilly and Company (NYSE:LLY ) BofA Securities 2025 Health Care Conference Call May 15, 2025 11:40 AM ET Company Participants Lucas Montarce - CFO Mike Czapar - SVP, IR Conference Call Participants Tim Anderson - Bank of America Tim Anderson Thanks for joining us. I'm Tim Anderson, the U.S. Pharma and Biotech analyst at Bank of America.